开放合作的资产

自身免疫性疾病资产

自身免疫性疾病是继心血管疾病和癌症之后，全球第三大类疾病。全球自身免疫疾病药物市场规模超过1000亿美元。尽管诊断和治疗的及时性越来越受到重视，但临床上仍存在大量未满足的需求。新靶点药物市场预计将持续扩大，其市场份额有望显著提升。

为什么选择百奥赛图的自身免疫性疾病相关抗体资产？

我们专有的全人抗体RenMice平台中拥有100多个自免类抗体项目
我们的平台包括RenMab、RenLite和RenNano，适用于开发具有高亲和力和强效阻断活性的单克隆抗体（mAbs）、双特异性抗体（bsAbs）、双特异性抗体药物偶联物（bsADCs）及VHH抗体
现成的治疗性抗体可用于多种适应症，包括哮喘、银屑病、移植物排斥、特应性皮炎、系统性红斑狼疮和类风湿关节炎
我们提供多种合作模式，包括抗体授权、转让及联合开发，并已与众多行业领先企业建立合作关系。欢迎与我们携手合作，共同为全球自身免疫疾病患者带来改变！

开放合作的自身免疫性疾病抗体项目

Target(s)	Format	Immune mice	Indication	Development Stage
CD40	mAb	RenMab	Graft rejection	Preclinical
IL4RA	mAb	RenMab KO	Asthma	Candidates Selection
0X40	BpAb	RenLite KO	Atopic dermatitis	Candidates Selection
ST2	mAb	RenMab KO	Asthma, Chronic Obstructive Pulmonary Disease (COPD)	Candidates Selection
TNFSF15 (TL1A)	mAb	RenMab KO	Enteritis	Candidates Selection
0X40	mAb	RenMab KO	Atopic dermatitis	Leads Selection
0X40L	mAb	RenMab KO, RenLite	Atopic dermatitis	Leads Selection
FCER1	mAb	RenMab KO	Asthma	Leads Selection
IGHE	mAb	RenMab KO	Asthma, Allergy, Allergic rhinitis	Leads Selection
IL23R	mAb	RenMab KO	Psoriasis,Enteritis	Leads Selection
1L2RB	mAb	RenMab,RenMab KO	Vitiligo, Alopecia areata, Graft rejection	Leads Selection
IL36R	mAb	RenMab KO	Psoriasis	Leads Selection
OSM	mAb	RenMab KO	Osteoporosis.Peripheral neuropathy	Leads Selection
OSMR	mAb	RenMab KO	Pruritus, atopic dermatitis, nodular pruritus, inflammatory bowel disease, pulmonary fibrosis,liver fibrosis	Leads Selection
CXCL13	mAb	RenMab,RenMab KO	Autoimmune disease	Leads Selection
BAFF	mAb	RenMab KO	Systemic lupus erythematosus (SLE), lgA nephropathy, Sjögren's syndrome, rheumatoid arthritis	Hits Selection
CCR9	mAb	RenLite KO	Inflammatory Bowel Disease	Hits Selection
CD6	mAb	RenMab KO	Psoriasis	Hits Selection
CD83	mAb	RenMab KO	Graft versus host disease, inflammatory disease, Transplant rejection	Hits Selection
DC-SIGN	mAb	RenMab KO	Systemic lupus erythematosus	Hits Selection
FCGR2A	mAb	RenMab KO	Asthma	Hits Selection
FCRN	mAb	RenMab KO	Myasthenia gravis,thrombocytopenia	Hits Selection
IFNAR1	mAb	RenMab KO	Chronic inflammation	Hits Selection
IL13	mAb	RenLite	Asthma	Hits Selection
IL17RB	mAb	RenMab KO	Psoriasis	Hits Selection
IL25	mAb	RenMab KO	Asthma	Hits Selection
IL31	mAb	RenMab KO	Atopic dermatitis	Hits Selection
IL4	mAb	RenMab	Asthma	Hits Selection
IL5R	mAb	RenMab KO	Asthma	Hits Selection
IL7RA	mAb	RenMab KO	Graft rejection, Allergic disease, Blood tumor	Hits Selection
ITGB7	mAb	RenMab KO	DSS induces enteritis	Hits Selection
KIT	mAb	RenMab	Hematopoietic stem cell transplantation, Chronic granulomatous disease, AML. GIST	Hits Selection
MADCAM1	mAb	RenMab KO	Inflammatory Bowel Disease	Hits Selection
MDL-1	mAb	RenMab KO	Inflammatory bowel Disease	Hits Selection
TSLP	mAb	RenMab, RenMab KO	Asthma, Atopic Dermatitis, chronic Obstructive Pulmonary Diseases (COPD)	Hits Selection